Posted by Michael Wonder on 23 Oct 2023
FDA approves Cabtreo (clindamycin phosphate, adapalene and benzoyl peroxide) topical gel for the treatment of acne vulgaris in patients twelve years of age and older
20 October 2023 - First and only FDA approved fixed dose, triple combination topical treatment.
Bausch Health and its dermatology business, Ortho Dermatologics, today announced that the US FDA has approved the new drug application for Cabtreo (clindamycin phosphate, adapalene and benzoyl peroxide) topical gel 1.2%/0.15%/3.1%, indicated for the topical treatment of acne vulgaris in patients twelve years of age and older.
